Can Depression Drugs Fight Cancer? USC Aims to Find Out

USC Trustee Daniel Tsai invests in a potential anticancer strategy that unites U.S. and Taiwanese scientists.
USC Trustee Daniel Tsai invests in a potential anticancer strategy that unites U.S. and Taiwanese scientists.
USC Viterbi alum uses data science to determine possible causes for rising costs of prescriptions.
A newly recruited team of biochemists is poised to disrupt the future of pharmaceutical development and advance personalized medicine.
A protein that makes other proteins also regulates fat levels in worms and may do so in humans, USC researchers say.
School of Pharmacy’s Sarah Hamm-Alvarez is one of 17 nationwide scientists to be honored.
Victoria Cho is one of only two interns invited to work at an international federation’s headquarters.
Researchers used a molecule to disrupt two key protein interactions that contribute to cancer growth.
Keck School neuroscientists have unlocked a piece of the puzzle in the fight against the debilitating neurological disorder that robs people of their motor skills.
A USC study is part of a national conversation to find evidence-based interventions that lower health care costs.
An experimental drug appears to reduce brain damage, eliminate brain hemorrhaging and improve motor skills in older stroke-afflicted mice and stroke-afflicted rats.
Only 5 percent of potential cancer drugs make it from Phase I clinical trial to FDA approval, but J. Jean Cui beat the odds.
Postdoctoral research associate Ivan Krylov PhD ’12 and PhD chemistry students Melissa Williams, Candy Hwang and Elena Ferri have more than one thing in common.
Pioneering institutions Allergan Inc. and the USC School of Pharmacy celebrated two of their visionary past leaders, Gavin S. Herbert and John A. Biles, along with the fellowship program that the two men established decades ago, at a luncheon in Irvine on Feb. 8.